XORTX Therapeutics Inc. (XRTX.V) TSXV

1.10

-0.02(-1.79%)

Updated at October 03 11:06AM

Currency In CAD

XORTX Therapeutics Inc.

Address

421 – 7th Avenue SW

Vancouver, BC T2P 4K9

Canada

Phone

403 455 7727

Sector

Healthcare

Industry

Biotechnology

Employees

2

First IPO Date

November 05, 2021

Key Executives

NameTitlePayYear Born
Dr. Allen Warren Davidoff Ph.D.Founder, Chief Executive Officer, President & Director546,6841960
Dr. Michael Scott Bumby D.V.M., M.B.A.Chief Financial Officer9,0941964
Dr. Stephen Haworth M.D., MRCPChief Medical Officer154,1621950
Dr. Stacy Evans M.B.A., M.D.Chief Business Officer219,8431974
Ms. Charlotte MayCorporate Secretary0N/A
Dr. David MacDonald Ph.D.Consultant of Clinical Operations01964
Dr. David Sans M.B.A., Ph.D.Director of Corporate Development01970
Nick RigopoulosDirector of Communications0N/A

Description

XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.